Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

July 30, 2028

Conditions
Behavioral InterventionViral Suppression of HIV InfectionART Adherence
Interventions
BEHAVIORAL

reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention

The reSTART intervention integrates a mobile health application, a urine tenofovir point-of-care self-test, and adherence feedback with motivational messages to increase HIV medication intake, reduce stimulant use, and improve HIV virologic suppression.

DEVICE

urine tenofovir point-of-care self-test

urine tenofovir point-of-care self-test

Trial Locations (1)

94110

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Florida International University

OTHER

collaborator

San Diego State University

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of California, San Francisco

OTHER

NCT07125235 - Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial | Biotech Hunter | Biotech Hunter